Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Financings

Amylyx Pharmaceuticals, Inc.

Financings

RaiseDate
Public offering of common stock
Made bigger: US$500.2M · US$35.5 a share · Leerink Partners +3
Dealers: Leerink Partners (co-lead), Morgan Stanley (co-lead), Guggenheim Securities (co-lead), LifeSci Capital (co-lead)
Use of proceeds: Pre-commercial activities for avexitide including manufacturing capacity, research and development, working capital and general corporate purposes
Aug 20, 2026
Public offering of common stock
Announced: US$175M · US$10 a share · Leerink Partners +2
Dealers: Leerink Partners (lead), Guggenheim Securities (lead), H.C. Wainwright & Co. (lead)
Use of proceeds: Avexitide commercial readiness, research and development, working capital and general corporate purposes
Sep 10, 2025
Public offering of common stock
Announced: about US$60M · US$3.5 a share · Leerink Partners
Dealers: Leerink Partners (lead)
Use of proceeds: Advance preparations for commercialization and pipeline programs, working capital and general corporate purposes
Jan 10, 2025

Read by 6ix AI from the company's releases